Global RNA Probe Market Overview:
RNA probes are stretches of single-stranded RNA that identify the presence of complementary nucleic acid sequences (also known as target sequences) through hybridization. In order to be detected, RNA probes are typically labeled, for instance with radioisotopes, epitopes, biotin, or fluorophores. North America is estimated to have most significant share in the market. The factors attributed to the growth are the high incidence rate of genetic disorders leading to congenital disabilities, developmental disabilities, and other metabolic syndromes.
|Unit||Value (USD Million)|
|Customization Scope||Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility|
RNA Probe Market Dynamics:
- Growing Incidence of Cancer and Hereditary Diseases
- Need To Develop RNA-Based Biomarkers and Measure RNA Expression Has Increased
- Exploitation of RNA Products as Weapons
- Stringent FDA Regulations for Laboratory Methods
|Road Blocks / Challenges|
- Lack of Skilled Professionals
- Emerging Infections and Rapidly Evolving Pathogens
- Very Sensitive To Degradation by RNase
|Gaps & Opportunities|
- Untapped Markets in Emerging Nations
Global RNA probe is a fragmented market due to the presence of various players. The players are focusing more on research and development. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are Sigma-Aldrich Co. LLC. (Argentina), Signet Laboratories, Inc. (United States), Kamiya Biomedical Co (United States), Sigma-Genosys (United States), Clontech Laboratories, Inc. (United States), Promega Corporation (United States), New England Biolabs (United States), Kaneka Eurogentec S.A. (Belgium), Advanced Cell Diagnostics, Inc. (United States), QIAGEN (Germany), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (United States), Danaher Corporation (United States) and Thermofisher Scientific (United States). Additionally, following companies can also be profiled that are part of our coverage like Abnova Corporation (Taiwan), BioGenex Laboratories (United States), Bio-Techne Corporation (United States) and Biocare Medical, and Bio SB (United States). Considering Market by Labels, the sub-segment i.e. Radioisotope will boost the RNA Probe market. Considering Market by End User, the sub-segment i.e. Clinical Research Institutes will boost the RNA Probe market.
Latest Market Insights:
In May 2021, New England Biolabs Inc., a leading supplier of life science reagents, had entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB.
In 2020, RNAscope ISH Detection Kit (Bio-Techne) received CE-IVD approval for BOND-III platform (Leica Biosystems) and In 2020, Creative Bioarray launched 2019 Novel Coronavirus Detection FISH probes to detect viral particles in infected cells & tissues.
What Can be Explored with the RNA Probe Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global RNA Probe Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in RNA Probe
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global RNA Probe market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in RNA Probe market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes RNA Probe Manufacturer, Raw Materials Supplier, Hospital & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and End User.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.